Penumbra Stock Price and Value Analysis

Penumbra (NYSE:PEN) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Penumbra to reach your target.

Target type

PEN Free Cash Flow Trend

Free Cash Flow trendline for PEN
Free Cash Flow trendline for Penumbra
CSV

Based on historical returns, we believe that Penumbra can grow its free cash at a rate of about 0%. That's positive!

AdvantagesDisadvantagesNeutral
None.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has wild ups and downs.
  • This company is making money at a modest rate.
  • This company pays no dividend.

Inside the PEN Numbers

PEN Price
(Penumbra stock price per share)
$319.12
[?] PEN Fair Price
(based on intrinsic value)
$36.22
[?] PEN Safety Price (based on a variable margin of safety) $21.73
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 298% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Devices stocks
[?] Free Cash Flow Jitter 279%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,403,093 shares shorted. With 38,300,534 shares available for purchase and an average trading volume over the past 10 trading days of 265,160, it would take at least 9.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2013 1321732 -4.2
2014 1321732 -8.7
2015 1321732 -24.1
2016 1321732 -18.8
2017 1321732 5.4
2018 1321732 19.8
2019 1321732 14
2020 1321732 -49.8
2021 1321732 -8.5
2022 1321732 -75.1
2023 1321732 76.8
2024 1321732 148
2025 1321732 211

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 11 fiscal years from 2013 to 2025 with positive net income, operating cash flow totaled $539 million against net income of $371 million, or 1.45 times. Net income was negative in 2 of the 13 years, and those years are left out of the ratio.

In 2025, operating cash flow was 1.34 times net income, compared with -3.50 times for the earliest three years (2013 to 2015).

In 2025, capital expenditures were $63.7 million, 26.7% of operating cash flow of $239 million, which leaves an estimated $175 million after capex. Across the 7 years with reported capex, it averaged 28.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2013 4.1 -3.4 0.8 -0.83
2014 2.2 -6.4 3.9 -2.85
2015 2.4 -20.7 5.5 -8.75
2016 14.8 -12.8 13.6 -0.86
2017 4.7 12.7 12.5 2.73
2018 6.6 28.8 9.6 4.36
2019 48.5 26.7 22.1 0.55
2020 -15.7 -33.2 24.8 n/a
2021 5.3 9.5 21.2 1.80
2022 -2 -55.7 19.3 n/a
2023 91 97.3 15.2 1.07
2024 14 168 21.2 12.02
2025 178 239 63.7 1.34

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 3 fiscal years from 2014 to 2024 with dividend or share repurchase facts, estimated free cash flow totaled $115 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 1 of the 3 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $100 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2024, cash spent repurchasing shares was $100 million, 67.8% of estimated free cash flow of $148 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2014 -8.7 n/a 1 1 n/a
2015 -24.1 n/a 0.3 0.3 n/a
2024 148 n/a 100 100 67.8%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $88.8 million in 2013 and $1,404 million in 2025, a compound annual growth rate of 25.9% over 12 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 17.5% from 2024 to 2025.

Our estimated free cash flow was $211 million in 2025, 15.0% of revenue. In 2013 the estimated margin was negative 4.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2013 88.8 -4.2 -4.7%
2014 126 -8.7 -7.0%
2015 186 -24.1 -12.9%
2016 263 -18.8 -7.1%
2017 334 5.4 1.6%
2018 445 19.8 4.4%
2019 547 14 2.6%
2020 560 -49.8 -8.9%
2021 748 -8.5 -1.1%
2022 847 -75.1 -8.9%
2023 1,059 76.8 7.3%
2024 1,195 148 12.4%
2025 1,404 211 15.0%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $187 million against total liabilities of $399 million, or 46.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 21.8% of total assets in 2025, compared with 110.2% in 2014, a decrease of 88.4 percentage points.

Stockholders equity was $1,428 million in 2025, up from negative equity of -$12.4 million in 2014.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 14.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2014 121 3.3 134 -12.4
2015 264 19.5 31.3 233
2016 308 13.2 41.7 267
2017 477 50.6 76.3 400
2018 515 67.8 92.6 422
2019 666 72.8 180 486
2020 823 69.7 185 638
2021 1,244 59.4 290 948
2022 1,371 69.9 372 999
2023 1,556 167 377 1,179
2024 1,533 324 382 1,151
2025 1,827 187 399 1,428

Price Versus Our Estimated Value

Positive free cash flow appears in 6 of the 13 fiscal years we hold for Penumbra from its current SEC filer.

At $319.12, Penumbra trades above our fair value estimate of $36.22.

Year-to-year variability in free cash flow is volatile, measured at 279%.

We do not have a dividend yield for Penumbra.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 298% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to Penumbra, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Penumbra (PEN) 12,578 80.4 - - 781% above
Baxter International (BAX) 13,135 - 0.2% 11.4% 61% below
Globus Medical (GMED) 8,861 16.5 - - 61% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.6% 24% below
Haemonetics Corporation (HAE) 5,472 53.2 - 1.7% 132% above
Merit Medical Systems (MMSI) 5,053 31.6 - 1.1% 117% above
LivaNova PLC (LIVN) 4,998 26.0 - - 317% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1321732.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 7 of the 13 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: PEN annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in PEN

Does Penumbra have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: PEN

This example shows how we apply the Trendshare checklist to PEN: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 319.12
    • Market cap: $13B
    • EPS: 3.97
  2. Step 2 — Valuation checks

    • P/E: 80.383
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.